Legal & General Group
CASI

Legal & General Group’s CASI Pharmaceuticals CASI Stock Holding History

Legal & General Group’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-691
Closed -$17K – 3508
2021
Q1 		$17K Sell
691
-115
-14% -$3.23K ﹤0.01% 3186
2020
Q4 		$24K Hold
806
– – ﹤0.01% 3015
2020
Q3 		$12K Sell
806
-47
-6% -$885 ﹤0.01% 3147
2020
Q2 		$21K Buy
853
+4
+0.5% +$87 ﹤0.01% 3045
2020
Q1 		$17K Sell
849
-269
-24% -$6.42K ﹤0.01% 2959
2019
Q4 		$35K Buy
1,118
+374
+50% +$12.1K ﹤0.01% 2973
2019
Q3 		$25K Hold
744
– – ﹤0.01% 3052
2019
Q2 		$24K Hold
744
– – ﹤0.01% 3123
2019
Q1 		$21K Hold
744
– – ﹤0.01% 3077
2018
Q4 		$30K Hold
744
– – ﹤0.01% 2901
2018
Q3 		$35K Hold
744
– – ﹤0.01% 2948
2018
Q2 		$61K Buy
+744
New +$50.2K ﹤0.01% 2662

Other funds holding CASI

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
IACGFIA
IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Legal & General Group's CASI Position: Q2 2021 in Review

Legal & General Group sold out of CASI Pharmaceuticals (CASI) in Q2 2021, closing a stake of 691 shares — an estimated $17K sold.

Legal & General Group first reported a position in CASI in Q2 2018 and held it in 12 quarters. The position peaked at $61K in Q2 2018. 68 funds tracked by Wall St. Rank hold CASI as of Q2 2021.

  • Legal & General Group reported no remaining CASI Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 691 CASI Pharmaceuticals shares in Q2 2021, an estimated $17K.
  • Legal & General Group first reported a position in CASI Pharmaceuticals in Q2 2018 and held it in 12 quarters.
  • Legal & General Group's CASI Pharmaceuticals position peaked at $61K in Q2 2018.
  • 68 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.